Regular Research ArticlesSertraline for the Treatment of Depression in Alzheimer Disease
Section snippets
Patients
Participants were recruited from memory clinics at five academic centers in the United States. Participants met criteria for dementia of AD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and had Mini-Mental State Examination scores22 from 10 to 26, inclusive. They also met criteria for depression of AD,4, 5 which compared with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for MDE requires the presence of three or
Demographics and Clinical Variables
A CONSORT flow chart of study recruitment and retention is in Fig. 1. One hundred thirty-one patients met eligibility criteria and were randomized: 67 to sertraline and 64 to placebo. Participants had a median age of 79 years, and 54% women, 67% were white, 21% African American, and 11% Hispanic/Latino (Table 1). A majority were married, living in their own home, and had at least a high school education. Participants randomized to sertraline had more years of formal education than those in the
DISCUSSION
During the course of 12 weeks, nearly 40% of the study population was judged to be either “better” or “much better” in terms of mood compared with baseline, and nearly 70% were judged at least “a bit better.” Moreover, depression severity, as measured by CSDD score, improved by nearly 50%. However, there were no significant differences between treatment groups on any of the three primary or secondary mood outcomes. In addition, sertraline treatment was associated with an increased rate of
References (34)
- et al.
Provisional diagnostic criteria for depression of Alzheimer disease
Am J Geriatr Psychiatry
(2002) - et al.
Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background
Am J Geriatr Psychiatry
(2002) - et al.
Depression in Alzheimer's disease: overview and treatment
Biol Psychiatry
(2002) - et al.
A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease
Am J Geriatr Psychiatry
(2000) - et al.
“Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician
J Psychiatr Res
(1975) - et al.
Design of depression in Alzheimer's disease study-2
Am J Geriatr Psychiatry
(2006) - et al.
Cornell Scale for Depression in Dementia
Biol Psychiatry
(1988) - et al.
Acute eosinophilic pneumonia associated to sertraline
Med Clin (Barc)
(2002) - et al.
Determinants of costs of care for patients with Alzheimer's disease
Int J Geriatr Psychiatry
(2006) - et al.
Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study
Int J Geriatr Psychiatry
(2008)
Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County Study
Int J Geriatr Psychiatry
Clinical application of operationalized criteria for ‘depression of Alzheimer's disease’
Int J Geriatr Psychiatry
Evolution of depressive symptoms in Alzheimer disease: one-year follow-up
Alzheimer Dis Assoc Disord
The persistence of neuropsychiatric symptoms in dementia: the Cache County Study
Int J Geriatr Psychiatry
Treatment with antidepressants in patients with dementia—a nationwide register-based study
Int Psychogeriatr
Double-blind trial of imipramine in Alzheimer's disease patients with and without depression
Am J Psychiatry
The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study
Br J Psychiatry
Cited by (185)
Putative pathological mechanisms of late-life depression and Alzheimer's disease
2023, Brain ResearchAlzheimer’s Disease Pharmacology
2022, Comprehensive PharmacologyPreliminary Evidence That Cortical Amyloid Burden Predicts Poor Response to Antidepressant Medication Treatment in Cognitively Intact Individuals With Late-Life Depression
2021, American Journal of Geriatric PsychiatryNeuropsychiatric Aspects of Alzheimer Dementia: From Mechanism to Treatment
2020, Psychiatric Clinics of North AmericaMinor and subthreshold depressive disorders in Alzheimer's disease: A systematic review and meta-analysis of prevalence studies
2020, Journal of Affective DisordersCitation Excerpt :Although overall there was evidence of validity of the diagnostic criteria, results indicated that MinD in AD may be an heterogeneous condition, and that patients with MinD may experience higher levels of apathy. The Depression in Alzheimer's Disease Study-2 (DIADS-2) (Rosenberg et al., 2010; Drye et al., 2011) was a 24-week randomised, parallel, placebo controlled clinical trial evaluating efficacy of sertraline in people with mild to moderate AD that also met criteria for MinD (DSM-IV). Sertraline was not superior to placebo on the modified Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (mADCS-CGIC) at 12 weeks (odds ratio (OR) sertraline = 1.1, 95% CI: 0.4–3.1); or on CSDD scores at 12 (difference = −3, 95% CI: −6.5–0.8) and 24 weeks (difference = −0.2, 95% CI: −4–3.5) or on proportion of patients in remission at 12 (OR sertraline = 1.7, 95%CI: 0.5–6.5) or 24 weeks (OR sertraline = 0.8, 95% CI: 0.3–2.9).
Alzheimer’s disease and other neurocognitive disorders
2020, Handbook of Mental Health and Aging
This work was supported by grants from National Institute of Mental Health, 1U01MH066136, 1U01MH068014, 1U01MH066174, 1U01MH066175, 1U01MH066176, and 1U01MH066177.
All authors participated in data collection and revision of the paper. Drafting of the paper was done by P.B.R. Data analyses were performed by LTD, CF, BKM, and CLM.
These disclosures refer to the period between 7/1/02 and 10/31/08, and include any anticipated conflicts through 12/31/09, according to the DIADS-2 Conflict of Interest Policy (available upon request from the study PI).
- •
Barbara K. Martin is involved in another trial for which Pfizer donated a different drug.
- •
Paul B. Rosenberg has received research funds from Pfizer, Elan, Lilly and Merck in amounts greater than $10,000.
- •
Jacobo Mintzer has received research support from Abbot to study donepezil and divalproex sodium, from AstraZeneca to study quetiapine, from BMS to study aripiprazole, from Eli Lilly to study olanzapine, from Forest to study both citalopram and memantine, from Janssen to study galantamine and risperidone, and from Pfizer to study donepezil and memantine; Dr. Mintzer also has been a consultant, paid directly or indirectly, for AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer, Forest, and Aventis. He also has been an unpaid consultant for Targacept and has participated in Speaker's Bureaus for Janssen, Forest, and Pfizer.
- •
Daniel Weintraub has received research support from Boehringer Ingelheim; Dr. Weintraub also has been a paid consultant for Acadia Pharmaceuticals, Novartis Pharmaceuticals, Boehringer Ingelheim, Osmotica Pharmaceutical, BrainCells Inc., EMD Serono, and Sanofi Aventis, and has participated on a Speaker's Bureau for Pfizer.
- •
Anton P. Porsteinsson is involved in research sponsored by Pfizer to study donepezil and PF04494700, Eli Lilly to study atomoxetine, a gamma-secretase inhibitor and a beta amyloid antibody, Wyeth to study a beta amyloid antibody, GSK to study a PPAR inhibitor and Forest to study memantine and neramexane; Dr. Porsteinsson has been a paid consultant and participated on a Speaker's Bureau for Pfizer and Forest.
- •
Lon S. Schneider is involved in research sponsored by Pfizer; Dr. Schneider has been a paid consultant for Forest, GlaxoSmithKline, Lilly, Merck, and Wyeth.
- •
Constantine Frangakis has no conflict of interests.
- •
Lea T. Drye has no conflict of interests.
- •
Peter V. Rabins has participated on Speaker's Bureaus for Wyeth, Eli Lilly, and Pfizer, and has received reimbursement for legal testimony from Janssen Pharmaceutica.
- •
Cynthia A. Munro has no conflict of interests.
- •
Curtis L. Meinert is involved in another trial for which Pfizer donated a different drug; Dr. Meinert owns shares of GSK stock.
- •
Constantine G. Lyketsos was involved in another trial for which Pfizer donated a different drug; he also was involved in research sponsored by Forest to study escitalopram and citalopram and Pfizer to study sertraline and donepezil; Dr. Lyketsos served as a consultant for Organon, Eisai, GSK, Lilly, Wyeth, and Pfizer.
- •